BiotechTube

CTX131

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

T Cell Lymphoma

Conditions

T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia

Trial Timeline

Aug 13, 2024 → Nov 1, 2030

NCT ID
NCT06492304

About CTX131

CTX131 is a phase 1/2 stage product being developed by CRISPR Therapeutics for T Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06492304. Target conditions include T Cell Lymphoma, B Cell Lymphoma, Acute Myeloid Leukemia.

What happened to similar drugs?

20 of 20 similar drugs in T Cell Lymphoma were approved

Approved (20) Terminated (2) Active (0)
✅PexidartinibDaiichi SankyoApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅ONTAK (denileukin difitox, DAB389IL-2)EisaiApproved
✅ONTAKEisaiApproved
✅LenvatinibEisaiApproved
✅ONTAKEisaiApproved
✅MogamulizumabKyowa KirinApproved

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT06492304Phase 1/2Recruiting
NCT05795595Phase 1/2Completed

Competing Products

20 competing products in T Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
AFM24 + SNK01AffimedPhase 1/2
14
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
39
prednisoneKiniksa PharmaceuticalsPhase 2
29
BBP-398 with nivolumabBridgeBio PharmaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
SelpercatinibEli LillyPre-clinical
26
Pemetrexed + Cisplatin + Placebo + PemetrexedEli LillyPhase 3
40
NBTXR3NanobiotixPhase 1/2
33
Cemiplimab + CetuximabEli LillyPhase 2
42
PemetrexedEli LillyPre-clinical
26
pemetrexed + erlotinibEli LillyPhase 2
35
Necitumumab-Gemcitabine-CisplatinEli LillyPhase 2
27
LY3295668 ErbumineEli LillyPhase 1
29
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
FYB206 + FYB206 + KeytrudaFormycon AGPhase 3
22
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine aloneMAIA BiotechnologyPhase 3
37